Stay updated with breaking news from J clin onocol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Piqray®(alpelisib), in combination with fulvestrant is approved for appropriate advanced breast cancer patients with a PIK3CA mutation after disease progression following endocrine-based therapy, providing eligible patients with more treatment optionsThis treatment option represents more than 20 years of researc. ....